These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27904448)

  • 1. Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Skerget M; Skopec B; Zontar D; Cernelc P
    Radiol Oncol; 2016 Dec; 50(4):402-408. PubMed ID: 27904448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
    Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
    Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
    Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
    Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
    Putkonen M; Rauhala A; Pelliniemi TT; Remes K
    Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
    Kuan JW; Su AT; Wong SP; Sim XY; Toh SG; Ong TC; Rajasuriarr JS; Lim SH; Guan YK; Liew HK; Liew PK; Tan JT; Kori AN; Cheng YY; Tan SM; Chang KM
    Transfus Apher Sci; 2015 Oct; 53(2):196-204. PubMed ID: 25910537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
    Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R
    Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
    Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Mayani H; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR
    Ann Hematol; 2006 May; 85(5):308-14. PubMed ID: 16525786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
    Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
    Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
    Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
    Vanstraelen G; Frère P; Ngirabacu MC; Willems E; Fillet G; Beguin Y
    Exp Hematol; 2006 Mar; 34(3):382-8. PubMed ID: 16543072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
    Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study.
    Samaras P; Rütti MF; Seifert B; Bachmann H; Schanz U; Eisenring M; Renner C; Susanne Müller AM; Schmidt A; Mischo A; Fuchs I; Bargetzi M; Manz MG; Stupp R; Petrausch U; Stenner-Liewen F
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):694-699. PubMed ID: 29246820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
    Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
    Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.